...
acrv-img

Acrivon Therapeutics, Inc. Common Stock, Common Stock

ACRV

NMQ

$6.71

+$0.02

(0.3%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$208.30M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
220.05K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.19 L
$11.9 H
$6.71

About Acrivon Therapeutics, Inc. Common Stock, Common Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameACRVSectorS&P500
1-Week Return-4.96%-2.12%-3%
1-Month Return3.23%-3.42%-0.73%
3-Month Return-10.17%-11.13%2.87%
6-Month Return2.91%-5.74%7.17%
1-Year Return40.97%3.97%25.31%
3-Year Return-59.68%1.05%28.38%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue13.00K832.00K1.09M536.00K[{"date":"2020-12-31","value":1.19,"profit":true},{"date":"2021-12-31","value":75.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":48.95,"profit":true}]
Gross Profit(13.00K)(832.00K)(1.09M)(536.00K)[{"date":"2020-12-31","value":-1300000,"profit":false},{"date":"2021-12-31","value":-83200000,"profit":false},{"date":"2022-12-31","value":-109500000,"profit":false},{"date":"2023-12-31","value":-53600000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses3.17M16.18M32.66M66.70M[{"date":"2020-12-31","value":4.75,"profit":true},{"date":"2021-12-31","value":24.26,"profit":true},{"date":"2022-12-31","value":48.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(3.17M)(16.18M)(32.66M)(67.24M)[{"date":"2020-12-31","value":-316800000,"profit":false},{"date":"2021-12-31","value":-1618400000,"profit":false},{"date":"2022-12-31","value":-3265700000,"profit":false},{"date":"2023-12-31","value":-6723700000,"profit":false}]
Total Non-Operating Income/Expense----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(5.31M)(16.24M)(31.17M)(60.39M)[{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-3116700000,"profit":false},{"date":"2023-12-31","value":-6038800000,"profit":false}]
Income Taxes(193.30K)(199.56K)(1.49M)1.00[{"date":"2020-12-31","value":-19329700,"profit":false},{"date":"2021-12-31","value":-19955800,"profit":false},{"date":"2022-12-31","value":-149000000,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(5.31M)(16.24M)(31.17M)(50.06M)[{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-3116700000,"profit":false},{"date":"2023-12-31","value":-5006500000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(5.31M)(16.24M)(29.68M)(60.39M)[{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-2967700000,"profit":false},{"date":"2023-12-31","value":-6038800000,"profit":false}]
EPS (Diluted)--(1.31)(2.73)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-131,"profit":false},{"date":"2023-12-31","value":-273,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACRV
Cash Ratio 12.65
Current Ratio 12.75

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACRV
ROA (LTM) -24.41%
ROE (LTM) -37.78%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACRV
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACRV
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.08
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Acrivon Therapeutics, Inc. Common Stock share price today?

Acrivon Therapeutics, Inc. Common Stock (ACRV) share price today is $6.71

Can Indians buy Acrivon Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) on Vested. To buy Acrivon Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACRV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Acrivon Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) via the Vested app. You can start investing in Acrivon Therapeutics, Inc. Common Stock (ACRV) with a minimum investment of $1.

How to invest in Acrivon Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACRV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Acrivon Therapeutics, Inc. Common Stock shares
What is Acrivon Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $11.9. The 52-week low price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $3.19.

What is Acrivon Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Acrivon Therapeutics, Inc. Common Stock (ACRV) is

What is Acrivon Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 1.08

What is Acrivon Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 0.00%

What is the Market Cap of Acrivon Therapeutics, Inc. Common Stock?

The market capitalization of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $208.30M

What is Acrivon Therapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Acrivon Therapeutics, Inc. Common Stock is ACRV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top